enGene Holdings Inc. has announced positive preliminary results from the pivotal cohort of its LEGEND trial studying detalimogene voraplasmid (detalimogene, formerly EG-70) in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without concomitant papillary disease. The results showed an improved complete response rate of 62% at six months. Safety data from 125 patients demonstrated a favorable tolerability profile, with low rates of treatment-related adverse events (42%) and dose interruptions (1.6%). The company has not specified if these results have already been presented at a scientific meeting or will be presented in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein.